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Head and neck (H&N) cancer is one of the 
most common types of cancer worldwide, with 
approximately 1.5 million new cases and 0.9 mil-
lion deaths in 2018 alone [1]. In current clinical 
practice, a vast majority of patients with locally 
advanced H&N cancer require radiotherapy (RT), 
with or without concomitant chemotherapy. In the 
past decades, the treatment paradigm for RT has 
evolved from 3D conformal RT to intensity modu-
lated radiotherapy (IMRT), which is the current 
gold standard [2]. The highly conformal dose dis-
tributions produced by IMRT lead to steep dose 
AbstrAct
background: Unbiased analysis of the impact of adaptive radiotherapy (arT) is necessary to evaluate dosimetric benefit and 
optimize clinics’ workflows. The aim of the study was to assess the need for adaptive radiotherapy (arT) in head and neck 
(h&N) cancer patients using an automatic planning tool in a retrospective planning study.
Materials and methods: Thirty h&N patients treated with adaptive radiotherapy were analysed. patients had a cT scan for 
treatment planning and a verification cT during treatment according to the clinic’s protocol. considering these images, three 
plans were retrospectively generated using the icycle tool to simulate the scenarios with and without adaptation: 1) the 
optimized plan based on the planning cT; 2) the optimized plan based on the verification cT (arT-plan); 3) the plan obtained 
by considering treatment plan 1 re-calculated in the verification cT (non-arT plan). The dosimetric endpoints for both target 
volumes and Oar were compared between scenarios 2 and 3 and the spIDerplan used to evaluate plan quality.
results: The most significant impact of arT was found for the pTVs, which demonstrated decreased D98% in the non-arT 
plan. a general increase in the dose was observed for the Oar but only the spinal cord showed a statistical significance. The 
spIDerplan analysis indicated an overall loss of plan quality in the absence of arT.
conclusion: These results confirm the advantages of arT in h&N patients, especially for the coverage of target volumes. The 
usage of an automatic planning tool reduces planner-induced bias in the results, guaranteeing that the observed changes 
derive from the application of arT. 
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gradients surrounding the target volumes, which 
are extremely sensitive to positional errors and 
anatomic changes. This is particularly critical in 
H&N cases, since there are several  structures at 
risk very close, and sometimes overlapping with 
the target volumes [3].
In current practice, RT treatment plans are 
designed individually for each patient based on 
a planning computed tomography (p-CT), on 
which the target volumes and the surrounding 
organs at risk (OAR) are contoured by a radiation 
oncologist (RO), usually using also other image 
modalities, such as MRI or PET, and auto-seg-
mentation tools which are already available. In 
the course of RT treatments (typically consisting 
of 5 fractions per week over 5–7 weeks), several 
factors can lead to anatomic changes of both the 
target volumes and OAR leading to deviations 
between the actual anatomy of the patient and 
the one represented on the p-CT. These factors 
include daily setup variations, primary tumour 
or nodal volume regression or progression, al-
teration in muscle mass and/or fat distribution, 
fluid shift within the body and weight loss [3, 4]. 
If unnoticed or unattended, these changes might 
lead to discrepancies in dose delivery, namely 
underdosage of the target volume, with loss of tu-
mour control, and/or to overdosage of the normal 
structures, potentially producing unexpected side 
effects [5, 6]. In order to correct for day-to-day 
positioning errors relative to the p-CT, most cen-
tres perform Image Guided Radiotherapy (IGRT) 
where most of those mismatches are corrected 
through couch shifts. However, one of the main 
limitations of IGRT is that internal changes in 
size, shape or relative position of the target vol-
umes or OARs compared with the initial p-CT 
cannot be corrected by rigid translational and/or 
rotational couch shifts [7]. A possible solution to 
this problem is Adaptive Radiotherapy (ART), 
which aims at correcting anatomical modifica-
tions by adapting the initial dose plan to the cur-
rent patient status [8, 9]. This process requires 
repeated imaging with sufficient quality for treat-
ment planning, re-contouring and re-planning, 
and can be done either offline, between treatment 
fractions, or online immediately prior to a frac-
tion while the patient is lying on the treatment 
couch [9, 10]. The most frequently implemented 
type of ART is offline ART, where the needed ad-
justments are done between treatment sessions, 
since online ART (during a given treatment ses-
sion) requires advanced tools, such as automatic 
segmentation and planning, which are not com-
monly available for most centres. In this work, the 
term ART refers to offline ART.
Various studies have reported shrinkage of both 
primary and nodal tumours during RT treatments. 
A recent review by Morgan et al. [3] reported me-
dian shrinkage rates of the primary tumour ranging 
from 3% to 16% in the end of the second week of 
treatment (2 studies), 7% to 48% by the end of week 
4 (2 studies) and of 6% to 66% by the end of week 
7 (14 studies), with the involved nodes presenting 
similar results. These volumetric variations have 
been associated with dosimetric consequences, 
such as reduction of the minimum delivered dose 
and loss of homogeneity in the dose distribution 
on the target volumes [11–13]. Conversely, some 
studies report that, despite the existence of volume 
reduction, dosimetric coverage of target volumes 
tends to be robust to anatomical changes [14–16]. 
As for the organs at risk, Brouwer et al. [8] pub-
lished a comprehensive review analysing 51 papers 
that reported anatomical and dosimetric changes 
in several OARs. The most highlighted organs were 
the parotid glands which were reported to reduce 
during treatment (average of 26% ± 11%) and to 
receive higher doses than planned, with an aver-
age increase of 2.2 ± 2.6 Gy in the mean delivered 
dose. Furthermore, five studies found significant 
associations between these volume changes and 
complications such as increased xerostomia, re-
duced saliva production and increased mucositis, 
all of which leading to patient’s decreased quality 
of life [8]. Three studies reported the effects of RT 
on the submandibular glands, showing an average 
volume reduction of 22% (15–32%). Regarding 
the spinal cord and the brainstem, several authors 
reported an increase in the maximum dose or in 
the D1% (the dose that is received by 1% of the 
volume — the near-maximum dose), being the 
highest reported average increase of 0.2% per frac-
tion for the spinal cord and 0.09 Gy per fraction 
for the brainstem [8].
The purpose of this study is to assess the need 
for ART in H&N patients by evaluating the dosi-
metric impact of performing a replan in the course 
of treatment both on the target volumes and on 
seventeen OARs, using an automatic planning tool. 




In this study, data from 30 H&N patients treated 
with helical IMRT (Tomotherapy HD by Accuray 
unit) at the Portuguese Institute of Oncology Fran-
cisco Gentil in Coimbra, Portugal, between 2016 
and 2019, were retrospectively analysed. The data 
concerned 26 patients that had been treated with 
radical/curative intent and 4 with palliative intent. 
All patients underwent Adaptive Radiotherapy ac-
cording to the clinic’s protocol (described in the 
following section), with (22 patients) or without (8 
patients) concomitant chemotherapy. The treated 
head and neck sites are summarized in Table 2.
The majority (25 out of 30) of patients were pre-
scribed 69.96 Gy to the tumour planning target vol-
ume (PTV-T), with two patients being prescribed 
59.4 Gy and three being prescribed 50 Gy. The pre-
scription to the lymphatic nodes’ PTVs (PTV-N) 
was either 54 Gy or 59.4 Gy. There were 3 patients 
who were not prescribed dose to the lymph nodes 
(palliative cases). Depending on the prescription 
scheme, the treatment was delivered in either 33 (26 
patients), 28 (1 patient) or 20 (3 patients) fractions.
All patients were properly immobilized by 
a thermoplastic mask, and had a planning CT 
scan in treatment position acquired at a median of 
14.5 days before the start of treatment (range 6–20 
days), using the Somatom Sensation Open scanner 
from Siemens, with a 3 mm slice thickness. The 
target volumes were then manually delineated by 
the radiation oncologist on this CT scan with the 
help of a contrast-enhanced diagnostic CT, when-
ever available, which was co-registered with the 
planning CT. A 5 mm margin between the GTV 
and CTV and a 3 mm margin between the CTV 
and the PTV were considered, though the margins 
could have been subjected to adaptations for each 
table 1. summary of patients’ characteristics. The mean 
and standard deviation is shown for the age and initial 
weight.
Characteristic Value
age 61.4 ± 10.3
Gender (M/F) 27/3
T stage (1/2/3/4) 1/1/6/22
N stage (0/1/2/3/) 4/1/20/5
Initial weight [kg] 62.0 ± 15.1
table 2. summary of patients’ target volumes in the planning (pcT) and verification cT (vcT) by treatment site and treatment 
intent (radical and palliative). The mean ± standard deviation of the tumoral (pTV-T) and nodal (pTV-N1 homolateral, pTV-N2 
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specific clinical case. The OARs were delineated 
with the aid of an atlas-based auto segmentation 
system (ABAS V 2.0) which was locally configured, 
although verification and (if needed) correction 
of the structures by the radiation oncologist was 
always performed. The 17 structures considered in 
this study were the spinal cord, brainstem, parotid 
glands, thyroid, submandibular glands, mandible, 
constrictor muscle, oral cavity, lens, retinas, optic 
nerves, ears, chiasm, larynx, oesophagus, lungs and 
pituitary gland.
adaptive radiotherapy protocol
In the clinic’s routine practice, patients treated 
with Helical Tomotherapy undergo a daily mega-
voltage CT (MV-CT) scan, before each treatment 
fraction, to identify the differences between the 
current treatment position and the one established 
in the p-CT. The MV-CT is the CTrue scan mode 
in tomotherapy which uses the 6MV beam tuned to 
3.5 MV and the acquisition pitch corresponds to 3 
mm thickness reconstructed images. 
A rigid registration is then performed between 
the MV-CT and the p-CT, and a transformation 
vector calculated, which is translated into rigid 
couch and roll angle shifts to correct for positional 
errors. 
If significant discrepancies between the imag-
es are observed after the couch corrections, the 
medical physicist is alerted, and a dose calculation 
is performed on the daily scan using the Planned 
Adaptive software module version 5.1.0.6 from Ac-
curay. This dose distribution is then revised by the 
responsible radiation oncologist who determines if 
a new treatment plan is needed. Usually, a differ-
ence over 3% in the PTV minimum dose leads to 
re-planning. Also, the risk of overdosage in critical 
structures, such as the spinal cord, would lead to 
re-planning; however, the initial treatment plan has 
usually spinal doses well below tolerance. 
If a replan is required, a second CT (verification 
CT) is acquired following the same protocol as the 
planning CT which consists of 3 mm slice thickness 
on a dedicated big-bore CT simulator (Siemens 
Sensation Open). Both the target volumes and OAR 
are propagated from the p-CT to the verification 
CT by rigid and deformable image registration us-
ing Velocity AI, version 3.2. These volumes are then 
manually corrected by the radiation oncologist and 
a new plan is calculated.
All patients in the study were treated using Adap-
tive Radiotherapy, following the clinic’s established 
protocol described above. The verification CT was 
acquired at an average of 18 days (median = 14 days, 
standard deviation = 10 days) after the start of treat-
ment. The volumes of the targets (both tumoral and 
nodal) are shown in Table 2 for the planning and ver-
ification CT by treatment site and treatment intent.
automatic plans generation
For each patient in the cohort, three new dose 
distributions were generated for the exclusive pur-
pose of the present study: 
• the dose distribution generated by the automatic 
planning tool iCycle17, based on the planning 
CT. This plan represents the original treatment 
plan;
• the dose distribution generated by the automatic 
planning tool iCycle17, based on the verification 
CT. This plan was generated independently from 
the original plan and represents the scenario 
where adaptation occurs (ART-plan);
• the dose distribution obtained by applying the 
fluence and beam arrangement resulting from 
the original plan in 1), but now calculated on 
the verification CT. This plan represents the hy-
pothetical scenario where no adaptation occurs, 
and the original plan would be delivered un-
til the end of treatment despite the anatomical 
modifications in the patient (non-ART plan).
In iCycle [17], plan generation is guided by 
a user defined wish-list, which contains both clini-
cal constraints that must be strictly met, and priori-
tized objectives to be optimized. The optimization 
occurs through a constraint-based method, which 
generates a single Pareto optimal IMRT solution 
for a given set of beams. The wish-list used for the 
generation of the original and ART plans (scenarios 
1 and 2) were built according to the guidelines es-
tablished by Ventura et al. [18].  
Dosimetric analysis
The dosimetric endpoints for both target vol-
umes and OARs were compared between the adap-
tive and the non-adaptive plan, to assess the impact 
of ART. For the target volumes the dose received 
by 98% of the volume (D98%) was considered and, 
for the OARs, the maximum and mean doses were 
considered for organs with serial and parallel archi-
tectures, respectively. 
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The normality and homogeneity of the variance 
were assessed using the Shapiro-Wilk normality 
test and Levene’s test, respectively, in order to de-
termine whether parametric or non-parametric 
tests were suitable. Then, since all variables were 
non-parametric, the Wilcoxon sign ranked test, 
with a significance level of 0.05, was used to assess 
statistical significance.
Quality assessment and comparison of 
plans
The dose distributions obtained for the 
ART-plan and the non-ART plan were assessed 
and compared using the SPIDERplan quality as-
sessment tool. This tool, described in detail by 
Ventura et al. [19] scores each structure of inter-
est using a score function based on targets/OAR 
clinical constraints. These scores are inversely pro-
portional to the quality of the plan regarding that 
structure, meaning that the closer the score is to 
zero the better the sparing of the OAR or coverage 
of the target volume is. A score lower than unity 
is achieved when all planning aims are met, and 
a score higher than 1 means that the plan does 
not comply with the required dose constraints. 
The structures are organized within groups and 
weights, which reflect the radiation oncologist’s 
clinical preferences, are assigned to both groups 
and structures. The scores associated with each 
structure are then combined so that group scores 
and a global plan score reflecting the clinical pref-
erences are calculated. The results are then pre-
sented in an intuitive graphical representation 
through customized radar plots.
In this study, the structures were divided into 
six groups (PTV group, Critical group, DigestOral 
group, Bone group, Optics group and Other group) 
which were assigned different weights (50%, 30%, 
5%, 3.5%, 10% and 1.5%, respectively) [18]. The dif-
ferent group structures are established based on in-
stitutional or international protocols, depending on 
factors like the pathology and clinical preferences, 
and the different weights were assigned according 
to the group clinical relevance [19]. 
All automatic plans were retrospectively generat-
ed using the imaging data available from the treated 
patients, with no extra images being acquired for 
the purpose of this work. Furthermore, all clini-
cal and imaging data were completely anonymized 
prior to the inclusion in the study.
results
The results of the dosimetric and the SPIDER-
plan quality analysis for every target volume and 
each OAR are shown in Table 3. The structures 
are organized in the table by the respective SPI-
DERplan groups, starting with the PTV group, and 
moving sequentially to the Critical, DigestOral, 
Bone, Optics and Other groups. 
Figure 1 shows the SPIDERplan plot for a repre-
sentative patient. The red line represents the struc-
tures’ scores for the ART plan and the yellow line, 
the scores for the non-ART plan. It is clear that the 
scores for the ART plan are generally closer to the 
centre of the plot, meaning that they  comply better 
with the aimed/tolerance value. The largest differ-
ences are observed for the target volumes (PTV 
group), and for the DigestOral group. Furthermore, 
for this specific patient, a significant improvement 
is achieved in the spinal cord with the ART plan 
clearly complying with the dose constraint for this 
OAR (score below 1), which is not the case for the 
non-ART plan (score above the radius 1 circle in 
the diagram). In fact, the scores in the ART plan 
are all bellow 1 (inner circle) with the exception of 
the thyroid, while the majority of the structures in 
the non-ART plan present a score above 1, meaning 
that the required clinical constraints for plan accep-
tance are not achieved in this scenario.
Discussion
In this work, thirty H&N cancer patients clini-
cally treated with adaptive radiotherapy were ret-
rospectively analysed in order to determine the do-
simetric consequences that would have occurred in 
the absence of adaptation.
The dosimetric analysis was performed for all 
target volumes as well as seventeen OARs, provid-
ing a holistic view of the dosimetric consequences 
of ART for the quality of the planned treatment. 
Looking at the dosimetric differences reported 
in Table 3, the results show that the most signifi-
cant dosimetric impact of ART is observed in the 
target volumes, all of which presented much lower 
D98% (or near minimum doses) in the non-ART 
scenario. The differences are so important that the 
requirement of the coverage of 95% of the PTV by 
95% of the prescribed dose is not met on average 
by any target, leading to the conclusion that, in the 
Reports of Practical Oncology and Radiotherapy 2021, vol. 26, no. 3
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table 3. results of the dosimetric and spIDerplan analysis of the arT and non-arT plans. The pTV-T, pTV-N1, pTV-N2 and 
pTV-N correspond to the tumoral, nodal homolateral, nodal contralateral and nodal bilateral pTVs, respectively. For each 
target the correspondent prescription dose is shown in the structure column, and for every structure the reference dose 
according to the parameter in question (D98%/Dmax/Dmean) is presented. The dosimetric analysis regarding the specified 
parameter is followed by the group score for the respective group. The mean global plan scores are also presented. p-values 




Dose [Gy] Mean std Mean Std
D98% [Gy]
pTV-T (69 Gy) 66.46 67.30 0.73 58.00 8.32 0.000*
pTV-T (59.4 Gy) 56.43 56.93 0.49 54.83 1.38 **
pTV-T (50 Gy) 47.50 48.80 1.18 37.2 6.56 **
pTV-N1 (59.4 Gy) 56.43 58.31 1.05 44.46 13.20 0.000*
pTV-N2 (54 Gy) 51.30 52.88 0.39 40.60 10.39 0.026*
pTV-N2 (59.4 Gy) 56.43 57.34 0.68 49.73 7.69 0.002*
pTV-N (59 Gy) 56.43 58.52 1.19 32.83 18.27 0.000*
Group score pTV group 0.98 0.01 2.45 5.98 0.000*
Dmax [Gy]
spinal cord 45 35.58 10.57 41.52 13.45 0.017*
Brainstem 54 15.36 13.74 19.19 17.07 0.474
Group score critical group 0.54 0.20 0.65 0.25 0.070
Dmean [Gy]
Left parotid 26 23.46 8.99 26.41 11.97 0.512
right parotid 26 24.00 10.07 25.11 11.88 0.522
Oral cavity 45 29.36 9.67 28.45 9.84 0.695
Oesophagus 40 24.81 10.39 24.18 12.21 0.821
Larynx 45 33.33 8.56 31.64 11.76 0.678
right submandibular Gland 45 41.47 9.62 44.67 12.11 0.223
Left submandibular Gland 45 41.31 15.39 41.32 17.39 0.709
Lips 25 17.54 5.83 17.77 5.64 0.915
constrictor Muscle 45 40.83 12.12 40.71 13.78 0.726
Group score DigestOral group 0.79 0.28 0.82 0.30 0.773
Dmax [Gy] Mandible 66 63.11 13.55 65.75 14.41 0.069
Dmean [Gy]
right ear 45 6.58 9.20 9.62 12.85 0.959
Left ear 45 6.10 9.43 7.48 11.91 0.959
right cochlea 45 16.82 18.97 16.09 20.88 0.559
Left cochlea 45 10.38 17.87 12.13 22.37 0.515
Group score Bone group 0.58 0.35 0.61 0.36 0.751
Dmean [Gy]
right Lens 12 1.06 2.86 1.57 2.99 0.655
Left Lens 12 1.50 3.75 1.46 2.82 1.000
right Optic Nerve 50 4.76 11.61 6.92 15.01 0.655
Left Optic Nerve 50 6.57 14.66 8.90 17.24 0.634
right retina 45 1.66 4.35 2.50 5.13 0.490
Left retina 45 2.06 5.09 2.50 5.01 0.743
chiasm 50 2.73 6.10 5.54 12.37 0.884
Group score Optics group 0.18 0.45 0.24 0.49 0.490
Dmean [Gy]
right Lung 5 2.34 1.70 2.74 3.08 0.848
Left Lung 5 2.26 1.69 2.53 2.87 0.763
Thyroid 27.5 35.81 12.65 37.03 13.18 0.750
pituitary 60 3.03 10.01 3.97 10.85 0.961
Group score Other group 0.71 0.35 0.78 0.51 0.554
Global score plan score 0.77 0.09 1.62 3.34 0.000*
**For the tumoral volumes prescribed 59.4 and 50 Gy there were not enough patients in each group for a statistical analysis to be meaningful (2 and 3 patients, 
respectively)
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absence of a replan, dose coverage and tumoral 
control would be significantly impaired. 
In fact, under the non-ART scenario, only three 
patients met the tumour PTV clinical constraint of 
98% of the volume receiving at least 95% of the pre-
scribed dose. Regarding the nodal PTVs, there were 
also three patients who met this constraint, but 
no patient achieved this result for all their targets. 
In other words, in the absence of ART, there was 
always at least one target which did not meet the 
clinical objective for dose coverage. These results 
are in line with previously published works that sta-
blish a link between reduced tumoral coverage and 
the absence of replanning [13, 20], with one study 
by Castelli et al. (2018) [21] reporting tumour un-
derdosage in 76% of the 37 oropharyngeal patients 
included in their analysis during IMRT without 
adaptation.
These significant loss in target coverage may 
be associated with the anatomical modification of 
the target volumes, which has been reported to be 
common in H&N treatments3. As can be seen in 
Table 2, quite significant variations in the volume of 
the targets were observed between the planning and 
verification CTs. It is worth pointing out that these 
variations were not homogeneous and, while most 
sites presented an average reduction of the volumes, 
there were three sites where average growth was 
observed, as well as within the palliative patients. 
Nevertheless, this heterogeneity can be attributed 
to the small number of patients in each site, which 
is also evident in the high standard deviations of 
the volumes. 
Furthermore, it is also clear that the standard de-
viation of the doses is much higher in the non-ART 
scenario for all structures (Tab. 3). This greatly in-
creased variance implies that not performing ART 
could contribute to more unpredictable side effects. 
The actual dosimetric consequences are highly pa-
tient specific, reinforcing the need for an individual 
assessment and identification of patients for ART. 
These results are corroborated by the SPIDERplan 
Figure 1. spIDer plan radar plot for one representative patient. The red line represents the scores for the arT-plan for each 
structure and target volume while the yellow line shows the scores for the non-arT plan. The angular amplitude assigned to 
each structure reflects the magnitude of the weight attributed to the group to which the structure belongs. The dotted grey 
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score for the PTV group, with both mean value 
and standard deviation significantly higher for the 
non-ART scenario. This score is also the only of the 
six groups which is greater than one, meaning that 
the minimum clinical criterion is not met for the 
target volumes in the absence of a replan.
Regarding the OAR, most structures show 
an increase in the mean/maximum dose in the 
non-ART scenario, as can be seen in Table 3. The 
majority of the published literature on the do-
simetric impact of ART in OAR focuses on the 
parotid glands, due to their well-known radiosen-
sitivity which is associated with impaired salivary 
production, xerostomia and reduced quality of 
life [3, 8]. There are currently relatively few stud-
ies which focus on other OARs that can also have 
a significant impact on the patients’ life if overly 
irradiated, including highly critical organs, such 
as the spinal cord and the brainstem [3, 8]. Our 
results clearly show that, although there is an in-
crease in the mean dose to the parotids in the 
absence of ART, it is not statistically significant, 
and the most affected OAR is the spinal cord. The 
maximum dose to the spinal cord increased ap-
proximately 6 Gy in average, but a very high dose 
variation across patients was observed. This is in 
line with the results from other studies which re-
port excess dose to the spinal cord, with Hansen 
et al. [22] reporting an increase in the maximum 
dose ranging from 0.2 to 15.5 Gy in all patients of 
a 13-patient cohort, and Chitapanarux et al. [23] 
reporting a decrease in the Dmax to the spinal 
cord with ART in 95% of the patients in their co-
hort, with a dose difference ranging from 1.6 to 5.9 
Gy. The average maximum dose to the spinal cord 
is still below the clinical threshold of 45 Gy in the 
ART plans, even with the observed increase. How-
ever, it is reasonable to infer that this value could 
escalate above the limit in the upcoming weeks 
of treatment, if the increase is not detected, or be 
a drawback in case of a future tumour recurrence 
needing re-irradiation. 
There were no observed differences on the dosi-
metric impact of ART between the group which was 
prescribed 69.96 Gy (25 patients) and the remain-
ing patients (5 patients), meaning that the dosimet-
ric pattern when comparing ART and non-ART 
scenarios is not dependent on the prescribed dose, 
at least for the reduced patient sample included in 
our study.
Despite the most significant discrepancies emerg-
ing for the target volumes and the spinal cord, the 
SPIDERplan global score, which gives a measure of 
the overall plan quality by performing a weighted 
score of the six different groups of structures, is 
also significantly higher for the non-ART scenario, 
with a much higher standard deviation compared 
to the ART case. This shows that the individual dif-
ferences observed for each structure correspond, in 
fact, to an overall loss of plan quality, which could 
potentially lead to a lower treatment outcome. 
Radiotherapy treatment planning is still consid-
ered a combination of science and art, being highly 
dependent on planners’ experience and skills [24]. 
Due to the intrinsic complexity of the optimization 
task planners are faced with, it has been shown that 
inter and intra planner variability plays an impor-
tant role in the quality of the output plans [25]. 
This variability can introduce a bias in the studies 
assessing the impact of adaptive replanning, since 
not only the same planner can produce different 
quality plans at different time points, but also the 
adaptive plan may not be designed by the original 
medical physicist due to the clinic’s workload. Fur-
thermore, depending on the nature and degree of 
the anatomical modification leading to the need 
for adaptive planning, the second plan can be of 
a significantly higher or lower complexity than the 
first one. 
Additionally, when the second plan is built, the 
planner has already information regarding the 
original plan and, therefore, actively attempts to 
improve the dose distributions that were previously 
achieved. This can also introduce an improvement 
in the adaptive plan’s dose distribution that is not 
necessarily due to the necessity of adaptation aris-
ing from anatomic variations, skewing the dosimet-
ric analysis in the direction of a benefit from ART 
that may not be realistic.
All of these factors make it difficult to determine 
to which extent the observed dosimetric differences 
between the application or not of ART that have 
been found in the literature are in fact due to the 
adaptation of the plan, as opposed to the previously 
mentioned aspects.
To the best of our knowledge, this is the first 
study to use an automatic planning tool to gener-
ate the dose distributions corresponding to the 
adaptive and non-adaptive scenarios, thus elimi-
nating other sources of differences between the 
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plans and allowing for a more unbiased analysis of 
the dosimetric impact of ART both in targets and 
OAR. It is important to note that the iCycle tool 
is a powerful optimizer that inherently produces 
high quality dose distributions, which could be the 
reason why no statistically significant differences 
were found in most OARs.Although these results 
highlight the advantages of ART in head and neck 
patients, especially regarding the preservation of 
target coverage, the presented methodology has 
some limitations. The dose distributions are eval-
uated in a single time point of treatment with-
out considering the total delivered dose and the 
number of patients is relatively small. Neverthe-
less, the results underline the necessity to include 
close monitoring of the target volume’s coverage in 
current clinical practice, to prevent severe target 
underdosage. Further research on the long-term 
impact of ART in patient survival and disease pro-
gression is still necessary to fully understand the 
impact and necessity of incorporating ART into 
routine clinical practice.
conclusion
This study shows that the introduction of one 
adaptive replan during treatment translates into 
statistically significant differences in the coverage 
of the target volumes as well as the dose to OAR. 
Of the seventeen analysed OARs, most showed in-
creased doses without ART, with the spinal cord 
presenting the only statistically significant differ-
ences. Overall plan quality was also impaired with-
out ART, as is shown by a significant increase in the 
global plan score obtained using the SPIDERplan 
assessment tool when compared with ART. 
The usage of an automatic planning tool elimi-
nates any bias arising from inter/intra planner vari-
ability, guaranteeing that the observed dosimetric 





This study has been funded by national funds, 
through FCT, Portuguese Science Foundation, un-
der projects POCI-01-0145-FEDER-028030 and 
UIDB/00308/2020.
acknowledgments
The authors would like to express their gratitude to 
Sebastiaan Breedveld and Ben Heijmen for making 
available the multicriterial optimization of IMRT 
plans system iCycle.
references
1. Bray F, Ferlay J, soerjomataram I, et al. Global cancer 
statistics 2018: GLOBOcaN estimates of incidence and 
mortality worldwide for 36 cancers in 185 countries. 
ca cancer J clin. 2018; 68(6): 394–424, doi: 10.3322/
caac.21492, indexed in pubmed: 30207593.
2. chin D, Boyle GM, porceddu s, et al. head and neck cancer: 
past, present and future. expert rev anticancer Ther. 2006; 
6(7): 1111–1118, doi: 10.1586/14737140.6.7.1111, indexed 
in pubmed: 16831082.
3. Morgan he, sher DJ. adaptive radiotherapy for head and 
neck cancer. cancers head Neck. 2020; 5: 1, doi: 10.1186/
s41199-019-0046-z, indexed in pubmed: 31938572.
4. castadot p, Lee Ja, Geets X, et al. adaptive radiotherapy 
of head and neck cancer. semin radiat Oncol. 2010; 20(2): 
84–93, doi: 10.1016/j.semradonc.2009.11.002, indexed in 
pubmed: 20219546.
5. Barker JL, Garden as, ang KK, et al. Quantification of 
volumetric and geometric changes occurring during 
fractionated radiotherapy for head-and-neck cancer us-
ing an integrated cT/linear accelerator system. Int J ra-
diat Oncol Biol phys. 2004; 59(4): 960–970, doi: 10.1016/j.
ijrobp.2003.12.024, indexed in pubmed: 15234029.
6. Yousuf a, Qureshi B, hussain a, et al. sU-e-J-81: adap-
tive radiotherapy for IMrT head & Neck patient in 
aKUh. Med phys. 2015; 42(6 part 8): 3282–3282, 
doi: 10.1118/1.4924168.
7. Yan Di, Lockman D, Martinez a, et al. computed tom-
ography guided management of interfractional patient 
variation. semin radiat Oncol. 2005; 15(3): 168–179, 
doi: 10.1016/j.semradonc.2005.01.007, indexed in 
pubmed: 15983942.
8. Brouwer cL, steenbakkers rJ, Langendijk Ja, et al. Identify-
ing patients who may benefit from adaptive radiotherapy: 
Does the literature on anatomic and dosimetric changes 
in head and neck organs at risk during radiotherapy pro-
vide information to help? radiother Oncol. 2015; 115(3): 
285–294, doi: 10.1016/j.radonc.2015.05.018, indexed in 
pubmed: 26094076.
9. Böck M. On adaptation cost and tractability in robust 
adaptive radiation therapy optimization. Med phys. 2020; 
47(7): 2791–2804, doi: 10.1002/mp.14167, indexed in 
pubmed: 32275778.
10. Green OL, henke Le, hugo GD. practical clinical Work-
flows for Online and Offline adaptive radiation Therapy. 
semin radiat Oncol. 2019; 29(3): 219–227, doi: 10.1016/j.
semradonc.2019.02.004,  indexed in  pubmed:
31027639.
11. Bhide sa, Davies M, Burke K, et al. Weekly volume and 
dosimetric changes during chemoradiotherapy with 
intensity-modulated radiation therapy for head and neck 
cancer: a prospective observational study. Int J radiat 
Oncol Biol phys. 2010; 76(5): 1360–1368, doi: 10.1016/j.
ijrobp.2009.04.005, indexed in pubmed: 20338474.
Reports of Practical Oncology and Radiotherapy 2021, vol. 26, no. 3
https://journals.viamedica.pl/rpor432
12. Mnejja W, Daoud h, Fourati N, et al. Dosimetric impact on 
changes in target volumes during intensity-modulated 
radiotherapy for nasopharyngeal carcinoma. rep pract 
Oncol radiother. 2020; 25(1): 41–45, doi: 10.1016/j.
rpor.2019.12.012, indexed in pubmed: 31889919.
13. ahn ph, chen cc, ahn aI, et al. adaptive planning in 
intensity-modulated radiation therapy for head and 
neck cancers: single-institution experience and clinical 
implications. Int J radiat Oncol Biol phys. 2011; 80(3): 
677–685, doi: 10.1016/j.ijrobp.2010.03.014, indexed in 
pubmed: 20619553.
14. castadot p, Geets X, Lee Ja, et al. adaptive functional 
image-guided IMrT in pharyngo-laryngeal squa-
mous cell carcinoma: is the gain in dose distribution 
worth the effort? radiother Oncol. 2011; 101(3): 
343–350, doi: 10.1016/j.radonc.2011.06.011, indexed in 
pubmed: 21724283.
15. O’Daniel Jc, Garden as, schwartz DL, et al. parotid gland 
dose in intensity-modulated radiotherapy for head and 
neck cancer: is what you plan what you get? Int J radiat 
Oncol Biol phys. 2007; 69(4): 1290–1296, doi: 10.1016/j.
ijrobp.2007.07.2345, indexed in pubmed: 17967319.
16. Wu Q, chi Y, chen pY, et al. adaptive replanning strategies 
accounting for shrinkage in head and neck IMrT. Int J ra-
diat Oncol Biol phys. 2009; 75(3): 924–932, doi: 10.1016/j.
ijrobp.2009.04.047, indexed in pubmed: 19801104.
17. Breedveld s, storchi prM, Voet pWJ, et al. icycle: Inte-
grated, multicriterial beam angle, and profile optimization 
for generation of coplanar and noncoplanar IMrT plans. 
Med phys. 2012; 39(2): 951–963, doi: 10.1118/1.3676689, 
indexed in pubmed: 22320804.
18. Ventura T, rocha h, da costa Ferreira B, et al. comparison 
of two beam angular optimization algorithms guided 
by automated multicriterial IMrT. phys Med. 2019; 64: 
210–221, doi: 10.1016/j.ejmp.2019.07.012, indexed in 
pubmed: 31515022.
19. Ventura T, Lopes M, Ferreira B, et al. spIDerplan: a tool to 
support decision-making in radiation therapy treatment 
plan assessment. rep pract Oncol radiother. 2016; 21(6): 
508–516, doi: 10.1016/j.rpor.2016.07.002, indexed in 
pubmed: 27698591.
20. Zhang p, simon a, rigaud B, et al. Optimal adaptive IMrT 
strategy to spare the parotid glands in oropharyngeal can-
cer. radiother Oncol. 2016; 120(1): 41–47, doi: 10.1016/j.
radonc.2016.05.028, indexed in pubmed: 27372223.
21. castelli J, simon a, rigaud B, et al. adaptive radiotherapy 
in head and neck cancer is required to avoid tumor under-
dose. acta Oncol. 2018; 57(9): 1267–1270, doi: 10.1080/0
284186X.2018.1468086, indexed in pubmed: 29706107.
22. hansen eK, Bucci MK, Quivey JM, et al. repeat cT imaging 
and replanning during the course of IMrT for head-and-
neck cancer. Int J radiat Oncol Biol phys. 2006; 64(2): 
355–362, doi: 10.1016/j.ijrobp.2005.07.957, indexed in 
pubmed: 16256277.
23. chitapanarux I, chomprasert K, Nobnaop W, et al. a dosi-
metric comparison of two-phase adaptive intensity-mod-
ulated radiotherapy for locally advanced nasopharyngeal 
cancer. J radiat res. 2015; 56(3): 529–538, doi: 10.1093/
jrr/rru119, indexed in pubmed: 25666189.
24. Breedveld s, craft D, haveren rv, et al. Multi-criteria opti-
mization and decision-making in radiotherapy. eur J Oper-
at res. 2019; 277(1): 1–19, doi: 10.1016/j.ejor.2018.08.019.
25. Batumalai V, Jameson MG, Forstner DF, et al. how 
important is dosimetrist experience for intensity 
modulated radiation therapy? a comparative analysis 
of a head and neck case. pract radiat Oncol. 2013; 3(3): 
e99–e9e106, doi: 10.1016/j.prro.2012.06.009, indexed in 
pubmed: 24674377.
